Accelmed Partners II, Lauxera Capital Partners Invest in Veranex

Veranex has forged strategic partnerships with Accelmed Partners II and Lauxera Capital Partners. Financial terms of the investments were not disclosed.

Accelmed and Lauxera join existing investor Summit Partners to help further accelerate Veranex’s strategic development as the company continues to expand its global operations. Uri Geiger, Ph.D., managing partner with Accelmed, and Samuel Levy, co-founder of Lauxera, have joined Veranex’s board of directors.

“In a very short time, Veranex has built a platform that provides our customers with integrated, multidisciplinary medical technology product development services,” said David Dockhorn, CEO of Veranex. “We are thrilled to welcome Accelmed and Lauxera to the Veranex team to help us continue building on this momentum. Each brings a wealth of experience that will support continued expansion of our geographic footprint, both operationally and commercially. We are very well-positioned for further growth and continued impact.”
 
Veranex serves the medical technology industry by providing design, engineering, regulatory, preclinical research, clinical development, commercial strategy, and market access services on an integrated basis. As a result, Veranex helps companies accelerate their speed to market while mitigating the cost and risk of MedTech product development. Since the company’s formation in 2021, Veranex has completed six acquisitions to build its position as the leading global product development services provider dedicated to the medical device and biotech space.
 
“Our team has a passion for healthcare innovation, and we see this same passion in the Veranex team,” said Geiger. “We look forward to supporting the Veranex team in building a unique, integrated solution that meets the MedTech industry’s needs in the areas of design, development, regulatory, and commercialization.”
 
“Europe is home to a vast ecosystem of innovative medical technology companies that can benefit from the wide-ranging services and capabilities Veranex delivers,” added Levy. “Veranex accelerates medical technology product development and, therefore, patient access to lifesaving MedTech innovations.”
 
Summit Partners, which invested in Veranex in 2021, retains majority ownership of Veranex in partnership with the Veranex management team.
 
Veranex is a tech-enabled service provider to the medical technology industry. Offering expert guidance for each of its four concept-through-commercialization pillars—engineering and design, clinical, market access, and regulatory—Veranex enables accelerated speed to market, controlled development costs, development risk mitigation, and accelerated market viability assessment.
 
Accelmed is a U.S.-based private equity firm focused on acquiring and investing in U.S. commercial stage, lower middle market HealthTech companies. Since 2009, Accelmed has deployed over $400 million into companies spanning medical devices, diagnostics, digital health and technology-enabled healthcare services. Accelmed seeks to accelerate value and scale innovation across the healthcare technology field by bringing to bear the team’s industry experience, operational and financial expertise, and strong global relationships. 
 
Founded in January 2020, Lauxera Capital Partners is an independent, healthcare technology-focused investment firm based in Paris and San Francisco. Its first fund, Lauxera Growth I, a €260 million vehicle, was reserved for professional investors and obtained the French government’s “Tibi” label for the financing of technology companies. Led by a team of life sciences business builders and professional healthcare investors with more than 50 years of experience, Lauxera makes growth and growth buyout investments in commercial-stage healthcare technology companies with the aim of driving business growth in the EU, U.S., and other international markets.